Literature DB >> 15300203

Chronic exposure of transforming growth factor beta 1 confers a more aggressive tumor phenotype through downregulation of p21(WAF1/CIP1) in conditionally immortalized pancreatic epithelial cells.

Daisuke Ito1, Koji Fujimoto, Ryuichiro Doi, Masayuki Koizumi, Eiji Toyoda, Tomohiko Mori, Kazuhiro Kami, Yoshiya Kawaguchi, Robert Whitehead, Masayuki Imamura.   

Abstract

BACKGROUND: Recent studies have demonstrated that transforming growth factor beta 1 (TGF-beta1) expression is markedly enhanced in invasive ductal pancreatic adenocarcinomas, although the precise role of TGF-beta1 in pancreatic carcinogenesis remains unclear. We analyzed TGF-beta1 expression in pancreatic intraepithelial neoplasias (PanINs) and the effects of chronic TGF-beta1 exposure on conditionally immortalized pancreatic epithelial (IMPE) cells.
METHODS: Sixty-one PanIN lesions were immunohistochemically stained with a polyclonal rabbit antibody against human TGF-beta1. Growth-inhibitory effects of short-term exposure to TGF-beta1 were examined in IMPE cells. IMPE cells resistant to TGF-beta1 (IMPE-Tr cells) were generated by continuous exposure to 1 ng/mL of TGF-beta1 for more than 50 days. Phenotypic alterations of IMPE-Tr cells were examined by soft agar and Matrigel assay and Western blot analysis. IMPE and IMPE-Tr cells were injected subcutaneously into nude mice for an in vivo tumorigenicity assay.
RESULTS: Forty-six percent of PanINs (28/61) were positive for TGF-beta1 expression, whereas all the epithelia of normal pancreatic ducts were negative. TGF-beta1 treatment showed the marked growth-inhibitory effects (>75%) in IMPE cells, whereas its effects were not observed in IMPE-Tr cells. IMPE-Tr cells were more spindle shaped compared with IMPE cells. In soft agar and Matrigel, formations of many colonies were observed in IMPE-Tr cells, but not in IMPE cells. Interestingly, the expression of p21(WAF1/CIP1) was induced by short-term exposure to TGF-beta1 in IMPE cells, whereas the induction was decreased in IMPE-Tr cells. All of the IMPE-Tr cell-injected mice (5/5) had subcutaneous tumors, although no tumor was found in the IMPE cell-injected mice.
CONCLUSIONS: TGF-beta1 expression in PanINs and neoplastic transformation of IMPE cells by long-term exposure to TGF-beta1 suggest that TGF-beta1 may act as a tumor promoter in the early stage of pancreatic carcinogenesis. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15300203     DOI: 10.1016/j.surg.2004.05.012

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  4 in total

1.  Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.

Authors:  Nabeel Bardeesy; Kuang-Hung Cheng; Justin H Berger; Gerald C Chu; Jessica Pahler; Peter Olson; Aram F Hezel; James Horner; Gregory Y Lauwers; Douglas Hanahan; Ronald A DePinho
Journal:  Genes Dev       Date:  2006-11-15       Impact factor: 11.361

2.  Transforming growth factor β-induced epithelial-mesenchymal transition increases cancer stem-like cells in the PANC-1 cell line.

Authors:  Hui Wang; Junli Wu; Ye Zhang; Xiaofeng Xue; Dong Tang; Zhongxu Yuan; Minyong Chen; Jishu Wei; Jingjing Zhang; Yi Miao
Journal:  Oncol Lett       Date:  2011-10-19       Impact factor: 2.967

3.  Expression of transforming growth factor-beta-1 and p27Kip1 in pancreatic adenocarcinomas: relation with cell-cycle-associated proteins and clinicopathologic characteristics.

Authors:  Nil Culhaci; Ozgul Sagol; Sedat Karademir; Huseyin Astarcioglu; Ibrahim Astarcioglu; Mujde Soyturk; Ilhan Oztop; Funda Obuz
Journal:  BMC Cancer       Date:  2005-08-08       Impact factor: 4.430

4.  Chronic TGFβ stimulation promotes the metastatic potential of lung cancer cells by Snail protein stabilization through integrin β3-Akt-GSK3β signaling.

Authors:  Gab-Yong Bae; Soon-Ki Hong; Jeong-Rak Park; Ok-Seon Kwon; Keun-Tae Kim; JaeHyung Koo; Ensel Oh; Hyuk-Jin Cha
Journal:  Oncotarget       Date:  2016-05-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.